Novel von willebrand factor targeting thrombolytic TGD001 is safe and well tolerated in a phase 1 first-in-human trial

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1ABSTRACT NUMBER: ESOC2026A1328 TGD001, A NOVEL VWF-TARGETING THROMBOLYTIC, EFFECTIVELY DEGRADES EX-VIVO HUMAN STROKE THROMBI AND DEMONSTRATES SAFETY AND ACTIVITY IN A PHASE 1 HEALTHY VOLUNTEER TRIAL2026
2. 2A first‐in‐human study of the anti‐inflammatory profibrinolytic TMS‐007, an SMTP family triprenyl phenol2022 · 14 citations
3. 3Thrombin‐Responsive Multiarmed Nanovesicles for Targeted Delivery of Tissue Plasminogen Activator and MRI‐Monitored Thrombolysis2026
4. 4A Phase 2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of sutacimig for prophylaxis in glanzmann thrombasthenia: A trial in progress2025
5. 5Recombinant ADAMTS13 prophylaxis in patients with congenital thrombotic thrombocytopenic purpura: Final analysis from A phase 3 randomized, controlled study2025